Pharma Industry News

New early breast cancer option recommended by NICE

The drug is recommended provided that Herceptin (trastuzumab) is the only HER2-directed adjuvant treatment people have had.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]